Trial record 3 of 30 for:
" July 20, 2011":" August 19, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Depression and ART Adherence in HIV+ Latinos
This study is ongoing, but not recruiting participants.
Sponsor:
University of Washington
Collaborators:
University of Texas
Information provided by:
University of Washington
ClinicalTrials.gov Identifier:
NCT01411839
First received: July 25, 2011
Last updated: August 23, 2011
Last verified: August 2011
- Full Text View
- Tabular View
- No Study Results Posted
- Disclaimer
- How to Read a Study Record
Purpose
The current HIV treatment adherence project was designed to adapt culturally and then pilot test an empirically supported cognitive-behavioral therapy program for adherence and symptoms of depression (CBT-AD)with HIV+ Latinos living on the U.S.-Mexico Border.
| Condition | Intervention |
|---|---|
|
Depressive Symptoms HIV Infections |
Behavioral: Cognitive-Behavioral Therapy AD |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | Addressing Depression and ART Adherence in HIV+ Latinos on the U.S.-Mexico Border |
Resource links provided by NLM:
Further study details as provided by University of Washington:
Primary Outcome Measures:
- Montgomery-Asberg Depression Rating Scale (MADRS) [ Time Frame: Changes in depression ratings at two time points: From baseline to 6 and 9 month follow-up ] [ Designated as safety issue: No ]The MADRS is a 10-item clinician administered scripted rating scale of depressive symptoms. The scale was develop to capture current depressive symptoms within the past seven days. The areas covered include: apparant and reported sadness, inner tension, reduced sleep and appetite, concentration difficulties, lassitude, inability to feel, pessimistic and suicidal thoughts. Both control and treatment conditions are interviewed with the MADRS at baseline and at 6 and 9 month follow-ups for any changes.
Secondary Outcome Measures:
- Self-Report Adherence [ Time Frame: Changes in self-reported adherence from baseline through 9 months ] [ Designated as safety issue: No ]From the Visual Analogue Scale or brief items
- MedSignals Electronic Pill-box for Adherence [ Time Frame: Changes in adherence at two-time points: from baseline to 6 and 9 month follow-up ] [ Designated as safety issue: No ]The MedSignals electronic pill-box is a elecontric storage bin that allows participants to store medications. In the treatment condition, the pill-box provides audio commands to alarm participants of their dosing regimen. The pill-box stores adherence information (time, number of openings). In the control condition, the pill-box does not alarm participants. The pill-box serves as a storage bin for the control condition and stores adherence data. All data is then uploaded onto an online database for investigators.
| Enrollment: | 40 |
| Study Start Date: | July 2008 |
| Estimated Study Completion Date: | September 2011 |
| Estimated Primary Completion Date: | August 2011 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
|
Experimental: Cognitive-Behavioral Therapy (CBT-AD)
CBT intervention for adherence and depression in a sample of HIV+ Latinos. The intervention is designed for issues of non-adherence and depressive symptomatology. Therapy intervention involves 10-weekly or biweekly sessions, with 2 booster session.
|
Behavioral: Cognitive-Behavioral Therapy AD
Therapeutic intervention, one-on-one and face-to-fact, over multiple sessions
Other Name: CBT-AD
|
|
No Intervention: Control-Standard Care
Those randomized to the control condition are not involved in the CBT-AD therapy intervention. They receive standard care as usual. A letter is sent to their medical provider indicating that mild symptoms of depression were detected. The participants in the control arm are followed and matched to a participant in the intervention arm.
|
Detailed Description:
Additionally, the investigators will assess the feasibility and efficacy of a novel medication monitoring and reminder system (MedSignals®) in the form of an electronic pillbox with monitoring and reminding functions that is available in a Spanish-language version. Our hypotheses are grounded in a conceptual model proposing that the CBT-AD intervention will improve problem-solving ability and decrease depressive symptomatology, which will directly improve biomedical outcomes of HIV-1 RNA viral load and CD4 as well as indirectly improve biomedical outcomes through increased motivation, improved memory, and better medication adherence. Evaluating and implementing generalizable and sustainable mental health and adherence interventions such as the ones proposed are urgently needed in the region to improve HIV treatment outcomes and thwart the development and transmission of drug resistant virus.
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Criteria
Inclusion Criteria:
- HIV+ participants (a) currently receiving HIV care at La Fe CARE Center (study site);
- 18 years of age or older;
- Latino (i.e., self-identified as being of Mexican heritage);
- English- or Spanish-speaking
- capable of giving informed consent;
- currently on a prescribed antiretroviral regimen;
- suboptimally adherent (i.e., demonstrated either by a VL load taken in the last 12 months that is above the undetectable threshold of 50 mL copies or self-reporting a missed dose in the last two weeks);
- exhibiting some depressive symptomatology (i.e., scoring on the Beck Depression Inventory-1A 10 or above), and (i) male or female (including transgender Female-to-Male and Male-To-Female.
Exclusion Criteria:
- actively psychotic or so cognitively impaired that they cannot participate,
- so physically ill as to be unable to come to the clinic to participate in the intervention, OR
- Report The use of crack, cocaine, heroin, OR methamphetamines to any extent in the past 40 days.
- Those who are planning on being away from the area for any extended period during the study (as in the case of seasonal workers) or whom
- have household members already enrolled in the study will also be excluded. We did choose to restrict study eligibility to individuals of Mexican descent.
Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01411839
Locations
| United States, Texas | |
| Centro de Salud Familiar La Fe CARE Center | |
| El Paso, Texas, United States, 79925 | |
Sponsors and Collaborators
University of Washington
University of Texas
Investigators
| Principal Investigator: | Jane M Simoni, Ph.D. | University of Washington |
More Information
No publications provided
| Responsible Party: | Jane M. Simoni, Ph.D., University of Washington |
| ClinicalTrials.gov Identifier: | NCT01411839 History of Changes |
| Other Study ID Numbers: | 35279-C, R34MH084674 |
| Study First Received: | July 25, 2011 |
| Last Updated: | August 23, 2011 |
| Health Authority: | United States: Institutional Review Board |
Keywords provided by University of Washington:
|
Depression Latinos Adherence Cognitive-Behavioral Therapy HIV/AIDS |
Additional relevant MeSH terms:
|
HIV Infections Acquired Immunodeficiency Syndrome Depression Depressive Disorder Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases |
Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases Immunologic Deficiency Syndromes Immune System Diseases Slow Virus Diseases Behavioral Symptoms Mood Disorders Mental Disorders |
ClinicalTrials.gov processed this record on May 21, 2013